TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06423833

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trendelenburg maneuver (TM)
Description: The investigator will measure changes in velocity time integral (VTI) and stroke volume (SV) during Trendelenburg maneuver (TM) in high-risk surgical patients by trans-thoracic Doppler echo cardiography.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Passive leg raising test
Description: The investigator will measure changes in velocity time integral (VTI) and stroke volume (SV) during Passive leg raising (PLR) test in high-risk surgical patients by trans-thoracic Doppler echo cardiography.
Study: NCT05791097

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusions will consist of a sterile, normal saline solution. Placebo will be administered on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab is a monoclonal antibody formulated for intravenous infusion. 200 mg of tislelizumab will be administered on Day 1 of each 21-day cycle
Study: NCT05354141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExoFlo
Description: Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
Study: NCT05354141

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline
Description: Placebo
Study: NCT05896592

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder check
Description: Assessment of arrhythmias recorded in the ILR. The procedure will be repeated at subsequent visits 3, 4, 6, 9, 12, 15, 18 months after randomization.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder check
Description: Assessment of arrhythmias recorded in the ILR. The procedure will be repeated at subsequent visits 3, 4, 6, 9, 12, 15, 18 months after randomization.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Holter ECG
Description: 24 hour ECG recording. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Holter ECG
Description: 24 hour ECG recording. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anamnesis
Description: Medical history assessing symptoms of bradycardia, MAS, paraMAS and complications of performed procedures. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anamnesis
Description: Medical history assessing symptoms of bradycardia, MAS, paraMAS and complications of performed procedures. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Anamnesis
Description: Medical history assessing symptoms of bradycardia, MAS, paraMAS and complications of performed procedures. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
Study: NCT04868877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-129
Description: full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-129
Description: full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET
Study: NCT06377553

Intervention type: DRUG
Intervention: Radiotracer Injection
Description: An intravenous catheter will be placed in an arm or hand vein for injection of \[68Ga\]CBP8;~6-10 mCi of \[68Ga\]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded; The catheter will be flushed with 0.9% saline solution; The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably.

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: MRI and PET scanner to be used:~3.0 T Laboratory (Bay 7) Siemens Biograph mMR.~Magnetic resonance images of the pelvis and abdomen will be acquired using the Martinos Center's combined 3 Tesla PET/MRI scanner. The image quality on these 3 Tesla devices will be very high, equivalent to or better than any other standard clinical MRI system. PET images of the target body site will be acquired when necessary, the data acquisition will be started shortly before radiotracer injection; Coincidence event data will be acquired and stored in list mode or compressed (i.e., sinogram space) format. Subjects will be asked to lie still for the duration of the study. The entire imaging session will last up to 120 minutes

Intervention type: OTHER
Intervention: Rectal Ultrasound Gel Injection
Description: About 50ml of ultrasound gel will be placed into the vagina using the blunt end of the ultrasound gel tube or a Foley catheter or a syringe with a blunt Christmas tree end. No ultrasound probe will be inserted into the vagina, no external ultrasound probe will be used. No ultrasound study will be performed. The ultrasound gel will only be used to distend the vagina and improve the quality of MRI images; this is standard of practice in MRI for endometriosis and for several other gynecological diseases.
Study: NCT04868877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-129
Description: full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-129
Description: full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-129
Description: full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-129
Description: full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-129
Description: full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Approved, 3rd-generation EGFR-TKI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Approved, 3rd-generation EGFR-TKI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: administrated by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: administrated by IV infusion
Study: NCT05671991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg vs Placebo
Description: Acute Study- Empagliflozin 25 mg vs Placebo on D1 then alternate therapy on D7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Chronic Study- Empagliflozin 10 mg for 8 weeks
Study: NCT06622824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX-826 0.5% BID
Description: 0.5% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX-826 1.0% BID
Description: 1.0% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (Placebo) applied BID
Description: Matching placebo applied topically to scalp twice daily for 24 weeks
Study: NCT06702215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-modal paired associative stimulation (cm-PAS) protocol
Description: The cross-modal Paired Associative Stimulation (cm-PAS) will consist of a visual stimulus depicting a hand being touched repeatedly paired with a transcranial magnetic stimulation (TMS) pulse delivered over the right primary somatosensory area, for a total of 150 paired stimuli delivered at a fixed frequency of 0.1 Hz. The time interval between the visual-touch onset and the TMS pulse will be 20 ms for the experimental session and 100 ms for the control session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-modal paired associative stimulation (cm-PAS) protocol
Description: The cross-modal Paired Associative Stimulation (cm-PAS) will consist of a visual stimulus depicting a hand being touched repeatedly paired with a transcranial magnetic stimulation (TMS) pulse delivered over the right primary somatosensory area, for a total of 150 paired stimuli delivered at a fixed frequency of 0.1 Hz. The time interval between the visual-touch onset and the TMS pulse will be 20 ms for the experimental session and 100 ms for the control session.
Study: NCT06701877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circle of security Parenting (COS-P)
Description: The Circle of Security Parenting® (COS-P) program is an attachment-based intervention designed to enhance caregiver sensitivity, parental reflective functioning, and the quality of the child's attachment to their caregiver. This manualized intervention, with both educational and therapeutic components, empowers caregivers to better understand and respond to their child's needs, fostering secure attachment (22).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traitement as usual (TAU)
Description: TAU typically involves home visits, educational and psychological support for foster carers and/or children in placement, and efforts to support and monitor contact between children and their birth families.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traitement as usual (TAU)
Description: TAU typically involves home visits, educational and psychological support for foster carers and/or children in placement, and efforts to support and monitor contact between children and their birth families.
Study: NCT04546126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Group 2)
Description: Participants will take 1 mg dexamethasone 2x a day for 3 days to suppress cortisol production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin (Group 3)
Description: Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PET/CT Scan with FNP-59
Description: FNP-59, a radiotracer, is administered for PET/CT scans.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PET/CT Scan with FNP-59
Description: FNP-59, a radiotracer, is administered for PET/CT scans.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PET/CT Scan with FNP-59
Description: FNP-59, a radiotracer, is administered for PET/CT scans.
Study: NCT06702371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindset Intervention
Description: The EMBody intervention contains seven short documentary-style films and paired reflection activities across three modules.~Module 1: Introducing Mindsets (Film 1: A New normal; Film 2: What is a Mindset?; Film 3: Your Body is Capable; Film 4: How to Choose Your Mindset).~Module 2: Challenges and Setbacks (Film 5: Living with Uncertainty; Film 6: The Long and Winding Road).~Module 3: Looking to the Future (Film 7: Opportunities Emerge).
Study: NCT06701071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: Clomiphene citrate is an estrogen receptor antagonist that leads to pituitary FSH release and prevention of the LH surge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate
Description: Clomiphene citrate is an estrogen receptor antagonist that leads to pituitary FSH release and prevention of the LH surge.
Study: NCT06700551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Each week, the investigator will send participants one topic through the chat function on the Zalo app. Before receiving the topic, participants will vote on which topic they would like to learn about. The topics will be presented as videos and will cover the following seven areas: providing everyday care, being a caregiver, self-care, knowledge about dementia, fall prevention, pressure injury prevention and care, and managing behavior changes.They may ask questions related to providing dementia care or share their feelings via the chat on the Zalo app.
Study: NCT06701240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ParentChild+
Description: 92-session early literacy focused intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FamilyNutrition+
Description: 92-session active control focused on child nutrition
Study: NCT06704139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine - .25 mg
Description: Fifty patients will receive intrathecal morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl + morphine
Description: Fifty patients will receive intrathecal morphine and fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron + Dexamethasone
Description: All patients will receive a compination of intravenous 4mg ondansteron and 8mg dexamethasone 15 minutes before spinal anathesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron + Dexamethasone
Description: All patients will receive a compination of intravenous 4mg ondansteron and 8mg dexamethasone 15 minutes before spinal anathesia
Study: NCT06701370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task Oriented Training
Description: Task oriented training consists of opening the bottlecap, stacking cubes on different sizes, buttoning,screwing, wearing a coat.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Bobath weightbearing and mobility exercises for upper extremity and 15 minutes Neuromuscular Electrical Stimulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Rehabilitation
Description: Bobath weightbearing and mobility exercises for upper extremity and 15 minutes Neuromuscular Electrical Stimulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper arm ergometer
Description: The patients will be rode 5 minutes forwardly and 5 minutes backwardly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper arm ergometer
Description: The patients will be rode 5 minutes forwardly and 5 minutes backwardly
Study: NCT06702566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 and PD-L1 inhibitor
Description: PD-1 inhibitor includes pembrolizumab，Nivolumab，Sintilimab，tislelizumab，Triplimab，Camrelizumab, Serplulimab.~PD-L1 inhibitor includes durvalumab,Atezolizumab,Adebrelimab,Envafolimab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted drugs
Description: Targeted drugs includes EGFR-TKIs,ALK-TKIs,Multitargeted Tyrosine Kinase Inhibitors, VEGF antibody, EGFR antibody, antibody-drug conjugates drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Targeted drugs
Description: Targeted drugs includes EGFR-TKIs,ALK-TKIs,Multitargeted Tyrosine Kinase Inhibitors, VEGF antibody, EGFR antibody, antibody-drug conjugates drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy drugs
Description: Chemotherapy drugs are determined based on the investigator's decision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy drugs
Description: Chemotherapy drugs are determined based on the investigator's decision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy drugs
Description: Chemotherapy drugs are determined based on the investigator's decision.
Study: NCT04942964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bocidelpar
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bocidelpar
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bocidelpar
Description: Oral
Study: NCT04777591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine TAP block
Description: Group will receive Liposomal bupivacaine TAP block (mixed with plain bupivacaine) intraoperatively during free flap breast reconstruction as part of the multimodal pain control.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Group will receive plain bupivacaine TAP block intraoperatively during free flap breast reconstruction as part of the multimodal pain control.
Study: NCT05647694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V-NAV indoor navigation prototype
Description: Users will use the V-NAV prototype as an augmentation to their indoor navigation activities.
Study: NCT04590417

Intervention type: DRUG
Group type: OTHER
Intervention: Estradiol valerate 2 mg, cyproterone acetate 25 mg
Description: The entire study period will be approximately 1 year, which will include around 2 months of document preparation, 5 months of recruitment, 3 months of follow-up, and 2 months of data analysis.
Study: NCT05836571

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04528992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Therapy
Description: BFR is a rehabilitation method that involves wearing a tight band around the exercising extremity to briefly limit blood flow while doing light weight exercises. The response is similar to heavy weight training or lifting but without the stress on the extremity that is still healing from surgery. Will be given after 2 weeks standard postoperative physical therapy per surgeon's ACL reconstruction protocol following surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Postoperative Physical Therapy
Description: This is the surgeon's standard postoperative physical therapy protocol after ACL reconstruction.
Study: NCT05392712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetometer
Description: inspection equipment for magnetocardiography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetometer
Description: inspection equipment for magnetocardiography

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetometer
Description: inspection equipment for magnetocardiography
Study: NCT05752396

Intervention type: OTHER
Intervention: Conditioned Pain Modulation
Description: Conditioned pain modulation (CPM) procedure evaluates the change in mechanical and heat pain sensitivity by a contralateral conditioning stimulus (cold immersion). This psychophysical paradigm investigates inhibitory pain modulation processes.

Intervention type: OTHER
Intervention: Conditioned Pain Modulation
Description: Conditioned pain modulation (CPM) procedure evaluates the change in mechanical and heat pain sensitivity by a contralateral conditioning stimulus (cold immersion). This psychophysical paradigm investigates inhibitory pain modulation processes.

Intervention type: OTHER
Intervention: Conditioned Pain Modulation
Description: Conditioned pain modulation (CPM) procedure evaluates the change in mechanical and heat pain sensitivity by a contralateral conditioning stimulus (cold immersion). This psychophysical paradigm investigates inhibitory pain modulation processes.
Study: NCT06572722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: atezolizumab adjuvant therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab neoadjuvant therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab neoadjuvant+adjuvant therapy
Study: NCT05889624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: During an 8-week active treatment, participants will receive 6 telehealth CBT sessions, followed by a maintenance phase (16 weeks) when participants will receive 3 booster CBT sessions. The sessions will be conducted by teletherapists from the Clinical Coordinating Center at Cincinnati Children's using a standardized treatment manual. A parent/legal guardian will be included in 2 sessions teaching ways to be active coaches, encouraging use of effective coping skills and refraining from reinforcement of maladaptive coping. Each session will be about 45 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: During an 8-week active treatment, participants will receive 6 telehealth CBT sessions, followed by a maintenance phase (16 weeks) when participants will receive 3 booster CBT sessions. The sessions will be conducted by teletherapists from the Clinical Coordinating Center at Cincinnati Children's using a standardized treatment manual. A parent/legal guardian will be included in 2 sessions teaching ways to be active coaches, encouraging use of effective coping skills and refraining from reinforcement of maladaptive coping. Each session will be about 45 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: During an 8-week active treatment, participants will begin taking a daily pill (amitriptyline) prescribed and managed clinically by the site headache provider. Amitriptyline will be taken once a day before bedtime. The weight based dosage will gradually be increased based on tolerability and a standardized titration protocol during the 8 week active treatment. The participant will remain on a maximum tolerated dose for the final 16 weeks (maintenance).